Psychedelic company focusing on developing an integrated functional mushroom brand specializing on health and wellness food market Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) announced having signed a psilocybin supply agreement deal with Halucenex Life Sciences Inc.
Halucenex is a wholly owned subsidiary of Creso Pharma Ltd (ASX: CPH) the company specializes on researching novel psychedelics compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.
Optimi confirmed that the agreement deal concerns entirety of the Company’s recently extracted first batch of psilocybe cubensis mushrooms at its Princeton, British Columbia facility. According to the agreement, Optimi Health will supply the mushrooms in in the form of whole, dried mushroom fruiting bodies to Halucenex.
“This first supply agreement, coming so soon after our first complete cultivation cycle, is a powerful affirmation of our decision to pursue the development of natural, GMP psilocybin. From this initial proof-of-concept batch, our cultivation team will continue to scale our operations to meet the demands of the sector, domestically and internationally with licensed entities and for individual patients within Canada according to the terms of the Special Access Program (SAP),” said Optimi’s CEO, Bill Ciprick.
On the other end, the chief executive officer of Halucnex Life Sciences, Bill Fleming, believes the agreement will be beneficial to both companies.
“We’re very excited to be moving forward on this supply agreement with the team at Optimi Health. Among our top priorities in the development of a psychedelic-assisted psychotherapeutic model for conditions such as anxiety and post-traumatic stress disorder has been to secure a safe, consistent supply of GMP psilocybin,” said Fleming.
